Posted by Michael Wonder on 29 Sep 2022
Catalyst Pharmaceuticals announces FDA approval of supplemental new drug application for Firdapse expanding patient population to include paediatric patients
29 September 2022 - Firdapse is now a treatment option for all LEMS patients 6 years of age and older in the US.
Catalyst Pharmaceuticals today announced that the US FDA has approved the supplemental new drug application to expand the indicated age range for Firdapse (amifampridine) 10 mg tablets to include paediatric patients, six years of age and older for the treatment of Lambert-Eaton myasthenic syndrome.
